Trial Profile
A Phase I-II Study of Dasatinib in Combination With Weekly Paclitaxel for Patients With Metastatic Breast Carcinoma.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Advanced breast cancer; Male breast cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Aug 2018 Status changed from active, no longer recruiting to completed.
- 19 Jan 2018 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
- 19 Jan 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.